Motherbase – dianosic

Entity

dianosic

Created in 2017
BETA

Up & running (A)
Existing signals show a regular activity
Social networks
2,611
Activities

deeptech
Technologies

Synthetic Biology
Entity types

Startup
Location

8 Pl. de L Hôpital, 67000 Strasbourg, France

Strasbourg

France
Employees

Scale: 11-50

Estimated: 14
Engaged corporates
11
4 2
Added in Motherbase
5 years ago

Description

Value proposition

"Smartly designed for you"

Dianosic ambitions to become a leading company in solving challenges in patient’s adherence to medication. We provide an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases.

Dianosic aims to fight against debilitating chronic diseases that affect millions of people. Our first focus is on chronic allergic rhinitis and chronic rhinosinusitis. Currently, 85% of allergic rhinitis patients are not compliant with their treatment. Furthermore, 20% to 25% of patients do not respond to first-line treatments. These medical challenges significantly impact patient’s quality of life.

We closely collaborate with healthcare professionals, including physicians in otorhinolaryngology (ENT) and neurosurgery. Our multidisciplinary team works hand in hand with them in order to design solutions that change physicians’ experience and offer patients minimally invasive and non-surgical options.

Dianosic develops ARIS, a unique platform that benefits from proprietary drug-eluting, long-term resorbable polymer. Our unique concept is meant to deliver patient centric, “insert and forget” solutions, maximizing patient quality of life and addressing physicians’ needs in terms of efficacy, safety, ease of use and patient adherence to treatment. Click here to learn more about our solutions: https://bit.ly/3Tnagog

📞 For more information, please contact us via LinkedIn private message, by mail (contact@dianosic.com) or phone (+33 1 44 04 45 80).

ENT, combination devices, drug-device combination, biotech, respiratory, Allergic rhinitis, Sinusitis, and Nose to brain
Original language

"Smartly designed for you"

Dianosic ambitions to become a leading company in solving challenges in patient’s adherence to medication. We provide an alternative to daily medication by designing a unique sustained intranasal drug delivery solution for respiratory and chronic central nervous system diseases.

Dianosic aims to fight against debilitating chronic diseases that affect millions of people. Our first focus is on chronic allergic rhinitis and chronic rhinosinusitis. Currently, 85% of allergic rhinitis patients are not compliant with their treatment. Furthermore, 20% to 25% of patients do not respond to first-line treatments. These medical challenges significantly impact patient’s quality of life.

We closely collaborate with healthcare professionals, including physicians in otorhinolaryngology (ENT) and neurosurgery. Our multidisciplinary team works hand in hand with them in order to design solutions that change physicians’ experience and offer patients minimally invasive and non-surgical options.

Dianosic develops ARIS, a unique platform that benefits from proprietary drug-eluting, long-term resorbable polymer. Our unique concept is meant to deliver patient centric, “insert and forget” solutions, maximizing patient quality of life and addressing physicians’ needs in terms of efficacy, safety, ease of use and patient adherence to treatment. Click here to learn more about our solutions: https://bit.ly/3Tnagog

📞 For more information, please contact us via LinkedIn private message, by mail (contact@dianosic.com) or phone (+33 1 44 04 45 80).